Sanjay Garg
Professor of Pharmaceutical Science
View researcher profile

Organisation unit

College of Health School of Pharmacy and Biomedical Sciences

Location

Adelaide University
Profile of Sanjay Garg

About me

PIDG: Your Partner in Translational Pharmaceutical Research

Recent Media Releases 
3D Printing of Biodegradable anticancer drug film for liver cancer: UniSA and 7News
3D Printing of Oesophageal stents for anticancer drug delivery: UniSA and 7News
US FDA Approval and commercial launch of a Vaginal Contraceptive: UniSA and 7News
Improved Bioavailability of Curcumin: UniSA and 7News

Introduction
Professor Garg is a pharmaceutical scientist committed to advancing drug discovery, development, and delivery to transform the lives of human and animal patients. With a PhD in Pharmaceutical Sciences, a Master's degree in Management, and a passion for innovation, he leads translational research that bridges cutting-edge science with practical healthcare solutions. As Academic Lead for Pharmaceutical Sciences, Co-Director of the Centre for Pharmaceutical Innovation (CPI) and Director of the Pharmaceutical Innovation and Development Group (PIDG), he drives development of novel therapeutics and delivery systems. His patented formulations have achieved significant global impact, including Acidform (USA Patent 6706276), a US FDA-approved non-hormonal contraceptive marketed in the USA as Phexxi, and other innovations that reached clinical stages and markets in India, New Zealand, the UK, and Australia. 
Professor Garg is committed to fostering interdisciplinary collaboration, working closely with researchers, industry leaders, and healthcare professionals to deliver patient-centric solutions. He actively seeks partnerships to advance pharmaceutical sciences and improve global health outcomes.

Research Focus
Prof. Garg's current research focuses on several critical areas of importance, including:
Drug Targeting and Delivery: Exploring 3D printing for precise drug delivery, both locally and systemically.
Infections: Widely collaborating on novel antimicrobial compounds and formulations for human and veterinary applications, leading to successful patents and infection-fighting products, especially for resistant infections (AMR).
Veterinary Delivery Systems: Over two decades of expertise in veterinary pharmaceuticals, developing cutting-edge drug delivery technologies, dosage protocols, and ensuring safety and efficacy for various animal species. The team has successfully developed several marketed and under animal trial veterinary formulations for horses, dogs, cats, fish, pigs, cattle, and other animals. Long-acting equine omeprazole injection is an example. 
Other Patient-centric Projects: Ongoing work benefiting patients, including compounding and drug analysis in human milk.

Research Outputs
Throughout his career, Professor Garg's contributions have been exceptional:
298 peer-reviewed papers
101 patents
24 book chapters
4 edited books
Technology transfer for 15 products
Sanjay is a highly cited researcher with an h-index of 72 (Google Scholar), 60 (Scopus), and FWCI of 1.83. He has mentored 243 research scholars at all levels, including 9 current PhD students.  
PIDG: Your Partner in Translational Pharmaceutical Research Recent Media Releases 3D Printing of Biodegradable anticancer drug film for liver cancer: UniSA and 7News 3D Printing of Oesophageal stents for anticancer drug delivery: UniSA and 7News US FDA Approval and commercial launch of a Vaginal Contraceptive: UniSA and 7News Improved Bioavailability of Curcumin: UniSA and 7News Introduction Professor Garg is a pharmaceutical scientist committed to advancing drug discovery, development, and delivery to transform the lives of human and animal patients. With a PhD in Pharmaceutical Sciences, a Master's degree in Management, and a passion for innovation, he leads translational research that bridges cutting-edge science with practical healthcare solutions. As Academic Lead for Pharmaceutical Sciences, Co-Director of the Centre for Pharmaceutical Innovation (CPI) and Director of the Pharmaceutical Innovation and Development Group (PIDG), he drives development of novel therapeutics and delivery systems. His patented formulations have achieved significant global impact, including Acidform (USA Patent 6706276), a US FDA-approved non-hormonal contraceptive marketed in the USA as Phexxi, and other innovations that reached clinical stages and markets in India, New Zealand, the UK, and Australia. Professor Garg is committed to fostering interdisciplinary collaboration, working closely with researchers, industry leaders, and healthcare professionals to deliver patient-centric solutions...
Read more Read less

Prof Garg's accolades include the Research and Enterprise Excellence Senior Career Researcher of 2025,  Supervisor of 2023, the Australasian Pharmaceutical Science Association Medal, the Research Impact Awards finalist at UniSA, the President's Medal from the South Australian Indian Medical Association, the Butland Award for Excellence in Research Supervision, and the Fellowship of the Indian Pharmaceutical Association.

Collaborations
Professor Garg champions international engagement, serving as Co-Director of the China-Australia Centre for Health Science Research (Shandong University, China) and holding adjunct appointments with the International Medical University (IMU, Malaysia) and Manipal Academy of Higher Education (MAHE, India).  He continues to seek new opportunities for national and international research collaboration and exchange.

From 2003 to 2012, Prof. Garg served as Deputy Head of the Pharmacy School at the University of Auckland, where he established a Good Laboratory Practice (GLP)-compliant analytical laboratory and played a pivotal role in developing research and postgraduate programs, thereby nurturing the next generation of pharmaceutical scientists.

Prof Sanjay Garg Chairs the expert group on substandard and falsified medicines for the World Organisation of Animal Health (WOAH).
Last updated on 08/01/2026 by Sanjay Garg